CAJ | 학술논문

支气管哮喘(简称哮喘)是以气道高反应为特征的慢性气道炎症.目前哮喘的治疗局限在控制临床症状上,因此应用更广泛的治疗手段亟待大家去探索.CD4-T淋巴细胞在哮喘的气道炎症、黏液产生、气道高反应性中起了极其重要的作用.近年来有研究发现热休克蛋白60(heat shock protein 60,HSP 60)能够介导CD4-T淋巴细胞的分化,提示HSP60可能成为治疗哮喘的新靶点,尤其是重症哮喘和难治性哮喘.本文旨在就目前的关于HSP60和哮喘关系的研究作一综述.
지기관효천(간칭효천)시이기도고반응위특정적만성기도염증.목전효천적치료국한재공제림상증상상,인차응용경엄범적치료수단극대대가거탐색.CD4-T림파세포재효천적기도염증、점액산생、기도고반응성중기료겁기중요적작용.근년래유연구발현열휴극단백60(heat shock protein 60,HSP 60)능구개도CD4-T림파세포적분화,제시HSP60가능성위치료효천적신파점,우기시중증효천화난치성효천.본문지재취목전적관우HSP60화효천관계적연구작일종술.
Bronchial asthma (asthma) is a chronic and complex airway inflammatory disease characterized by airway hyper-responsiveness.Current asthma therapies are limited to specific disease manifestations,highlighting the importance of developing treatments with broader treatment applications.CD4-T lymphocytes,which produce a characteristic repertoire of cytokines,play a critical role in the development of airway inflammation,mucus production and airway hyper-responsiveness in asthma.Recently,it has been demonstrated that heat shock protein 60 (HSP60) could mediate CD4-T lymphocyte differentiation,suggesting that HSP60 can be targeted in the development of novel anti asthma medications,especially for the treatment of severe disease or refractory patients.This review summarizes the current knowledge regarding the relationship between HSP60 and asthma.